# PRODUCT INFORMATION



# **Bimiralisib**

Item No. 23441

CAS Registry No.: 1225037-39-7

Formal Name: 5-(4,6-di-4-morpholinyl-1,3,5-triazin-2-

yl)-4-(trifluoromethyl)-2-pyridinamine


Synonym: PI3K-IN-2 MF:  $C_{17}H_{20}F_3N_7O_2$ 

FW: 411.4 **Purity:** ≥98%

 $\lambda_{max}$ : 203, 233, 279 nm UV/Vis.: Supplied as: A crystalline solid

Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



## **Laboratory Procedures**

Bimiralisib is supplied as a crystalline solid. A stock solution may be made by dissolving the bimiralisib in the solvent of choice, which should be purged with an inert gas. Bimiralisib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of bimiralisib in ethanol is approximately 2 mg/ml and approximately 10 mg/ml in DMSO and DMF.

#### Description

Bimiralisib is a potent and orally bioavailable inhibitor of phosphatidylinositol 3-kinases (PI3K;  $IC_{50}$ s = 33, 661, 708, and 451 nM for PI3K $\alpha$ , PI3K $\beta$ , PI3K $\gamma$ , and PI3K $\delta$ , respectively) and the mammalian target of rapamycin (mTOR; IC<sub>50</sub> = 89 nM).<sup>1</sup> It is selective for these kinases over a panel of cell surface and nuclear receptors, membrane channels, transporters, kinases, proteases, and phosphodiesterases at a concentration of 10  $\mu$ M. Bimiralisib has anticancer activity with an average GI<sub>50</sub> value of 0.7  $\mu$ M across the National Cancer Institute (NCI) 60 human cancer cell line panel. In vivo, bimiralisib (5-15 mg/kg) reduces tumor growth in a dose-dependent manner in a PC3 prostate cancer mouse xenograft model. Formulations containing bimiralisib are under clinical investigation for the treatment of relapsed and refractory lymphoma and advanced solid tumors.

#### Reference

1. Beaufils, F., Cmiljanovic, N., Cmiljanovic, V., et al. 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl) pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor as clinical candidate in oncology. J. Med. Chem. 60(17), 7524-7538 (2017).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

## WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 10/25/2022

### **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM